<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Health Forum</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Health Forum</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Health Forum</journal-title></journal-title-group><issn pub-type="epub">2689-0186</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10383010</article-id><article-id pub-id-type="pmcid-ver">PMC10383010.1</article-id><article-id pub-id-type="pmcaid">10383010</article-id><article-id pub-id-type="pmcaiid">10383010</article-id><article-id pub-id-type="pmid">37505489</article-id><article-id pub-id-type="doi">10.1001/jamahealthforum.2023.2247</article-id><article-id pub-id-type="publisher-id">aoi230049</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Urine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use Disorder</article-title><alt-title alt-title-type="headline">Urine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use Disorder</alt-title><alt-title alt-title-type="running-head">Urine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use Disorder</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Williams</surname><given-names initials="AR">Arthur Robin</given-names></name><degrees>MD</degrees><degrees>MBE</degrees><xref rid="aoi230049aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aoi230049aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rowe</surname><given-names initials="C">Christopher</given-names></name><degrees>PhD</degrees><xref rid="aoi230049aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gallagher</surname><given-names initials="R">Ryan</given-names></name><degrees>MD</degrees><xref rid="aoi230049aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aronowitz</surname><given-names initials="SV">Shoshana V.</given-names></name><degrees>PhD</degrees><xref rid="aoi230049aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aoi230049aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Diamond-Reivich,</surname><given-names initials="J">Jon</given-names></name><degrees>BA</degrees><xref rid="aoi230049aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bisaga</surname><given-names initials="A">Adam</given-names></name><degrees>MD</degrees><xref rid="aoi230049aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aoi230049aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aoi230049aff1"><label>1</label>Ophelia Health, Inc, New York, New York</aff><aff id="aoi230049aff2"><label>2</label>Research Foundation for Mental Hygiene, New York, New York</aff><aff id="aoi230049aff3"><label>3</label>University of Pennsylvania School of Nursing, Philadelphia</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> May 22, 2023.</p><p content-type="published-online"><bold>Published:</bold> July 28, 2023. doi:<uri content-type="doi">10.1001/jamahealthforum.2023.2247</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jamanetwork.com/pages/cc-by-nc-nd-license-permissions" ext-link-type="uri">CC-BY-NC-ND License</ext-link>. &#169; 2023 Williams AR et al. <italic toggle="yes">JAMA Health Forum</italic>.</p><corresp id="aoi230049cor1"><bold>Corresponding Author:</bold> Arthur Robin Williams, MD, MBE, New York State Psychiatric Institute, Department of Psychiatry, Columbia University, 1051 Riverside Dr, Office 3714, Unit 66, New York, NY 10032 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="aw2879@cumc.columbia.edu">aw2879@cumc.columbia.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Williams and Rowe had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Williams, Rowe, Gallagher, Aronowitz.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> All authors.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Williams, Rowe, Gallagher.</p><p><italic toggle="yes">Critical revision of the manuscript for important intellectual content:</italic> Williams, Rowe, Aronowitz, Diamond-Reivich, Bisaga.</p><p><italic toggle="yes">Statistical analysis:</italic> Williams, Rowe, Gallagher.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Williams, Gallagher, Diamond-Reivich.</p><p><italic toggle="yes">Supervision:</italic> Williams, Bisaga.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Williams reported personal fees from Ophelia Health, Inc, during the conduct of the study, and consulting fees from the National Quality Forum outside the submitted work. Dr Rowe reported being a paid employee of Ophelia Health, Inc, and receiving compensation in the form of equity and salary. Dr Gallagher reported financial support from Ophelia Health Inc during the conduct of the study. Dr Aronowitz reported personal fees (compensation for clinical work) from Ophelia Health, Inc, during the conduct of the study. Mr Diamond-Reivich reported being a paid employee of Ophelia Health, Inc, and receiving compensation in the form of equity and salary. Dr Bisaga reported personal fees from Ophelia Health, Inc, outside the submitted work.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> Funding was provided by Ophelia Health, Inc, a telehealth provider for opioid use disorder.</p><p><bold>Role of the Funder/Sponsor:</bold> Ophelia Health, Inc, had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-AOI230049-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p><p><bold>Additional Contributions: </bold>We would like to acknowledge contributions from Franco Marzella, PharmD, Clinical Operations Manager, Ophelia Health, Inc, regarding testing protocols and UDS product specifications. He received no additional compensation, outside of his usual salary, for these contributions.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2023-07-28T10:00"><day>28</day><month>7</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2023</year></pub-date><volume>4</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">441858</issue-id><elocation-id>e232247</elocation-id><history><date date-type="received"><day>17</day><month>2</month><year>2023</year></date><date date-type="accepted"><day>22</day><month>5</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>07</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>30</day><month>07</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-07-31 07:25:09.520"><day>31</day><month>07</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright 2023 Williams AR et al. <italic toggle="yes">JAMA Health Forum</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY-NC-ND License.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamahealthforum-e232247.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamahealthforum-e232247.pdf">jamahealthforum-e232247.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/channels/health-forum/fullarticle/10.1001/jamahealthforum.2023.2247"/><abstract abstract-type="teaser" specific-use="electronic"><p>This cohort study investigates the administration patterns and results of urine drug screening to assess its feasibility and patient outcomes in a telehealth-based opioid treatment setting.</p></abstract><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-aoi230049-1"><title>Question</title><p>Can routine urine drug testing be adapted to telehealth-based opioid treatment (TBOT) platforms for the treatment of opioid use disorder?</p></sec><sec id="ab-aoi230049-2"><title>Findings</title><p>In this cohort study of 3395 patients, urine drug testing was highly feasible and sustained throughout the duration of treatment, consistent with in-person settings. Rates of unexpected results were low throughout care.</p></sec><sec id="ab-aoi230049-3"><title>Meaning</title><p>Appropriate monitoring of buprenorphine adherence and patterns of drug use can be successfully adapted to TBOT settings.</p></sec></abstract><abstract><sec id="ab-aoi230049-4"><title>Importance</title><p>Amid rapid and widespread adoption of telehealth-based opioid treatment (TBOT), there is an urgent need for rigorous studies exploring the feasibility and characteristics of urine drug screening (UDS).</p></sec><sec id="ab-aoi230049-5"><title>Objective</title><p>To investigate administration patterns and results of UDS to assess feasibility of UDS and patient outcomes in a TBOT setting.</p></sec><sec id="ab-aoi230049-6"><title>Design</title><p>This observational cohort study was conducted between January 1, 2021, and December 6, 2022, and included patients with opioid use disorder treated in Ophelia, a TBOT treatment platform in 14 states. Data analysis was performed from January to March 2023.</p></sec><sec id="ab-aoi230049-7"><title>Main Outcomes and Measures</title><p>Number and percentage of patients with UDS within 30, 90, and 180 days of intake, grouped by adherence to clinical protocols. Associations were assessed between baseline characteristics and UDS completion and opioid positivity in first 30 days using &#967;<sup>2</sup> tests. Baseline and 180-day follow-up UDS results were compared using McNemar tests.</p></sec><sec id="ab-aoi230049-8"><title>Results</title><p>Among 3395 patients (mean [SD] age, 38.2 [9.3] years, mostly male [54.1%], non-Hispanic White [81.5%], urban-residing [80.3%], and cash-pay at intake [74.0%]), 2782 (83.3%) completed a UDS within 30 days (90.0% among protocol-adherent patients, 67.0% among protocol-nonadherent patients). A total of 2750 of 2817 (97.6%) patients retained more than 90 days completed 1 or more UDS, as did 2307 of 2314 (99.7%) patients retained more than 180 days. Younger patients, patients of a racial and ethnic minority group, those living in urban areas, and cash-pay patients were less likely to complete a UDS in the first 30 days. Buprenorphine positivity increased (from 96.9% to 98.4%, <italic toggle="yes">P</italic>&#8201;=&#8201;.004) and opioid positivity declined (from 7.9% to 3.3%, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001) over time.</p></sec><sec id="ab-aoi230049-9"><title>Conclusions and Relevance</title><p>In this cohort study of patients with opioid use disorder receiving buprenorphine in a remote care environment, UDS was highly feasible, though early UDS completion rates varied across demographic subgroups. The prevalence of unexpected UDS results was low and declined over time in treatment.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-AOI230049"><title>Introduction</title><p>Buprenorphine is the most frequently prescribed medication for opioid use disorder (OUD) with upward of 1 million to 2 million individuals treated annually<sup><xref rid="aoi230049r1" ref-type="bibr">1</xref></sup> among an estimated 7.6 million individuals with OUD.<sup><xref rid="aoi230049r2" ref-type="bibr">2</xref></sup> It is the only form of opioid agonist treatment prescribed from a general office setting&#8212;known as office-based opioid treatment (OBOT)&#8212;and is predominantly prescribed among general practice settings rather than behavioral health specialty settings.<sup><xref rid="aoi230049r3" ref-type="bibr">3</xref>,<xref rid="aoi230049r4" ref-type="bibr">4</xref></sup> There is consensus among the National Academy of Medicine<sup><xref rid="aoi230049r5" ref-type="bibr">5</xref></sup> and national health agencies<sup><xref rid="aoi230049r6" ref-type="bibr">6</xref></sup> that buprenorphine is the first-line treatment for OUD, as it is highly effective at reducing opioid use, overdose, and all-cause mortality and improving quality of life.<sup><xref rid="aoi230049r7" ref-type="bibr">7</xref>,<xref rid="aoi230049r8" ref-type="bibr">8</xref>,<xref rid="aoi230049r9" ref-type="bibr">9</xref>,<xref rid="aoi230049r10" ref-type="bibr">10</xref></sup></p><p>Routine urine drug screening (UDS) to test for illicit substance use and adherence to buprenorphine treatment is commonplace in addiction treatment settings, in part due to billing and reimbursement implications.<sup><xref rid="aoi230049r11" ref-type="bibr">11</xref></sup> However, there is little consensus about testing schedules and how to respond to results,<sup><xref rid="aoi230049r12" ref-type="bibr">12</xref></sup> leading to great practice variation and inconsistencies even within the same clinical settings.<sup><xref rid="aoi230049r13" ref-type="bibr">13</xref>,<xref rid="aoi230049r14" ref-type="bibr">14</xref></sup> While UDS collection is typically routine in heavily monitored clinical trial protocols, which may skew published rates of UDS in the medical literature, these standards do not translate to usual care settings.<sup><xref rid="aoi230049r9" ref-type="bibr">9</xref>,<xref rid="aoi230049r15" ref-type="bibr">15</xref></sup> A large observational study using administrative claims found that only 80% of patients receiving buprenorphine for OUD completed a UDS at any point in 2016,<sup><xref rid="aoi230049r16" ref-type="bibr">16</xref></sup> highlighting that UDS administration in OBOT settings is far from universal. Despite widespread use, there is surprisingly sparse empirical literature to guide drug testing in OBOT settings.<sup><xref rid="aoi230049r11" ref-type="bibr">11</xref>,<xref rid="aoi230049r17" ref-type="bibr">17</xref>,<xref rid="aoi230049r18" ref-type="bibr">18</xref>,<xref rid="aoi230049r19" ref-type="bibr">19</xref></sup> Although there is a general premise that UDS is an important and useful part of OBOT delivery, there is not strong evidence that more frequent UDS improves patient outcomes.<sup><xref rid="aoi230049r9" ref-type="bibr">9</xref></sup> Furthermore, patients often report that they find routine drug testing (especially when observed) as demeaning and an invasion of privacy,<sup><xref rid="aoi230049r20" ref-type="bibr">20</xref></sup> and clinicians may be concerned that more frequent testing may undermine retention.<sup><xref rid="aoi230049r21" ref-type="bibr">21</xref></sup> American Society of Addiction Medicine guidelines for appropriate drug testing encourage UDS as a therapeutic rather than punitive tool and that testing frequency be determined on an individualized basis.<sup><xref rid="aoi230049r22" ref-type="bibr">22</xref></sup> In turn, some state agencies have discouraged excessive drug testing that is not patient centered as part of routine clinical practice.<sup><xref rid="aoi230049r23" ref-type="bibr">23</xref></sup> The absence of set protocols and a sole reliance on individualized clinical decisions can increase the risk of disparate testing based on factors like race and socioeconomic status, highlighting the need for more formal guidance.<sup><xref rid="aoi230049r17" ref-type="bibr">17</xref>,<xref rid="aoi230049r24" ref-type="bibr">24</xref>,<xref rid="aoi230049r25" ref-type="bibr">25</xref></sup></p><p>The COVID-19 pandemic instigated federal policy changes that allowed for expanded telehealth-based opioid treatment (TBOT).<sup><xref rid="aoi230049r26" ref-type="bibr">26</xref></sup> Multiple studies have found that TBOT may be associated with improved patient outcomes (eg, increased retention, decreased medically treated overdoses) relative to in-person OBOT.<sup><xref rid="aoi230049r27" ref-type="bibr">27</xref>,<xref rid="aoi230049r28" ref-type="bibr">28</xref></sup> Two studies documented decreases in UDS frequency concurrent with the COVID-19 pandemic and the corresponding expansion of TBOT,<sup><xref rid="aoi230049r29" ref-type="bibr">29</xref>,<xref rid="aoi230049r30" ref-type="bibr">30</xref></sup> likely driven by a reactive decision to reduce patients&#8217; exposure to COVID-19 as opposed to a proactive change in protocols.<sup><xref rid="aoi230049r31" ref-type="bibr">31</xref></sup> Amid the rapid and widespread adoption of TBOT, there is an urgent need for rigorous studies exploring the feasibility and characteristics of UDS in remote care settings.</p><p>To address this need and inform practice and policy in this nascent and evolving space, we investigated the administration and results of UDS among a cohort of patients receiving buprenorphine for the treatment of OUD from a virtual-first TBOT platform. The objective of the study was to assess the feasibility of UDS, patterns of UDS administration, and rates of unexpected results (ie, negative for buprenorphine, positive for other opioids).</p></sec><sec id="H1-2-AOI230049"><title>Methods</title><sec id="H2-1-AOI230049"><title>Study Setting and Patient Sample</title><p>We analyzed data from a cohort of individuals with OUD treated at Ophelia, a virtual-first TBOT platform in 14 states (although the patient sample was mostly located in 2 states; eTable 1 in <xref rid="note-AOI230049-1-s" ref-type="supplementary-material">Supplement 1</xref>). Patients were reached directly through online advertisements or word of mouth. The care model, medical visits and protocol, organizational structure, custom electronic health record, and care coordination services were all designed explicitly for remote care without requiring any in-person visits. In-network patients, predominantly Medicaid beneficiaries, used insurance. Patients who were out of network or uninsured paid $195 monthly to participate in synchronous video-based clinical visits, which did not include pharmacy costs associated with filling buprenorphine prescriptions. Eligible patients were prescribed buprenorphine at intake, seen weekly during the stabilization phase, then stepped down to biweekly and then monthly visits under a nurse care manager model. To be eligible for care, patients had to be English-speaking adults and meet <italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders</italic> (Fifth Edition) OUD criteria. Patients were considered ineligible if they required a higher level of care, such as for unstable psychiatric conditions (eg, active suicidality or psychosis), physical dependency on high doses of sedative hypnotics, severe alcohol use requiring detoxification, or enrollment in a methadone program with a dose greater than 80 mg per day.</p><p>The study sample included all patients who completed an intake visit between January 1, 2021, and June 6, 2022, received their first buprenorphine prescription within 7 days of their intake, and were retained 30 or more days. The study was reviewed and granted a waiver of informed consent by the Western (WCG) IRB owing to use of deidentified data, and reported in accordance with Strengthening the Reporting of Observational Studies in Epidemiology (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link>) reporting guideline for cohort studies.</p></sec><sec id="H2-2-AOI230049"><title>UDS Protocol</title><p>All patients were sent two 16-panel UDS kits. Subsequent UDS kits were sent to patients throughout the care episode such that they always had at least 1 kit on hand and were expected to have a kit with them at every follow-up appointment. Neither patients nor insurance plans were billed for UDS.</p><p>Clinical protocols and company culture encouraged the use of UDS to help assess treatment progress and guide the care team in treatment plan adjustments, foster open communication between patient and clinician, and monitor for buprenorphine diversion. If a patient had unexpected UDS results or was unwilling or could not perform a UDS, the prescribing clinician and care team determined appropriate next steps, which could include increasing visit frequency or, for patients who were previously stable and regularly seen by a nurse care manager, escalating the patient back to regular visits with the prescribing clinician. Patients were not discharged solely due to unexpected UDS results.</p><p>The clinical protocol recommended that patients complete UDSs accordingly: approximately 1 week postinduction, when advancing from weekly to biweekly visits (typically 4 weeks postinduction), and when advancing from biweekly to monthly visits. Thereafter patients were expected to complete UDSs quarterly and additionally when clinically indicated. Patients self-administered UDSs off screen during visits, and clinicians visually inspected results and discussed them with the patient in real-time over video. Validity of urine specimens was assessed by confirming that temperature, creatinine, nitrite, pH, oxidants, glutaraldehyde, and specific gravity were all within normal ranges. The UDSs were conducted using the Know Drug Test Cup UDS kit (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cliawaived.com/know-drug-test-cups.html" ext-link-type="uri">https://cliawaived.com/know-drug-test-cups.html</ext-link>), except during April to June 2022, when the T-Cup Compact UDS kit (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://transmedco.com/t-cup-compact-16-panel-clia-waived-instant-drug-test-cup-with-etg-fyl-k2-tra-25-box/" ext-link-type="uri">https://transmedco.com/t-cup-compact-16-panel-clia-waived-instant-drug-test-cup-with-etg-fyl-k2-tra-25-box/</ext-link>) was used.</p></sec><sec id="H2-3-AOI230049"><title>Data Collection and Measures</title><p>Basic demographic information (date of birth, sex, gender, race and ethnicity, address) was collected via self-report in an online form prior to intake visits, and payment type at intake (ie, insurance vs cash) and for all visits was collected as part of routine billing. Race and ethnicity categories were modeled after those used by the US Census Bureau and grouped as follows: Hispanic/Latino, non-Hispanic African American, non-Hispanic White, and, due to small sample sizes of additional groups (non-Hispanic Asian, non-Hispanic Native American, non-Hispanic Pacific Islander, non-Hispanic multiple races), non-Hispanic other or multiple races. Patient urbanicity (ie, urban or rural) was defined using US Department of Agriculture rural-urban commuting area codes associated with the patient&#8217;s zip code, with codes of 1 to 3 denoting urban and 4 to 10 denoting rural locations.<sup><xref rid="aoi230049r32" ref-type="bibr">32</xref></sup> Dates and results of administered UDSs were collected as part of routine care. For this analysis, we report results for buprenorphine, opioids, methamphetamine, cocaine, benzodiazepines, amphetamines, alcohol, and cannabis. Treatment retention was defined using buprenorphine prescription data with discontinuation defined as a greater than 30-day gap in medication coverage. Patients were considered retained from the date of their first prescription through their last date covered by medication before a gap, or their last date covered by their most recent prescription for patients who had not discontinued within the study period.</p></sec><sec id="H2-4-AOI230049"><title>Statistical Analysis</title><p>We categorized patients into 1 of 3 groups based on UDS results in their first 30 days of care: opioid negative if the patient had at least 1 UDS and no opioid positive results, opioid positive if the patient had at least 1 opioid positive result, and no UDS (&#8220;missing&#8221;) if the patient had no UDS results. We examined associations between baseline patient characteristics and these groups using &#967;<sup>2</sup> and Fisher exact tests.</p><p>We calculated the number and percentage of patients who completed a UDS within 30, 90, and 180 days of starting treatment among patients retained for those minimums. We also calculated the time to first UDS, as well as the number of UDSs completed within the first 180 days of care among patients retained for 180 or more days.</p><p>Because our definition of retention allowed for gaps in buprenorphine coverage of up to 30 days, it is possible that patients retained for 30 days were only actively engaged in care for a small portion of that time, which could affect the likelihood of whether a patient completed a UDS early in care. To explore the association between UDS completion in the first 30 days of care and general patient engagement in care and treatment, we grouped patients by whether or not they were adherent to clinical protocols during that time. Patients were considered protocol adherent in the first 30 days if they completed at least 3 follow-up visits and had 7 or fewer days not covered by buprenorphine. We then assessed the number and percentage of patients who completed a UDS within 30 days, grouped by protocol adherence.</p><p>To explore variation in UDS completion by clinician and month in care, we summarized clinician-specific rates of completed UDS per patient-month for each month in care, which is described in eMethods in <xref rid="note-AOI230049-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p><p>To assess UDS results, we defined baseline UDS results as those corresponding to a patient&#8217;s first UDS within the first 30 days of treatment, and follow-up UDS results as those corresponding to a patient&#8217;s UDS closest to and within 60 days (before or after) of 180 days after starting treatment. We summarized the results of all baseline UDSs. We compared the results of patients&#8217; baseline and follow-up UDSs using McNemar test among a subsample of patients who were retained for at least 180 days and had both a baseline and follow-up UDS. We also conducted sensitivity analyses in which we redefined follow-up UDSs as those closest to and within 30 days (before or after) and 90 days (before or after) of 180 days in care. Patients included in the analysis comparing baseline and 180-day follow-up UDS results were likely not representative of all patients with baseline UDS results. To explore this, we compared baseline UDS results among patients who were included in the baseline/follow-up analysis (ie, who were retained for &#8805;180 days and had both a baseline and follow-up UDS) and those who were not using &#967;<sup>2</sup> tests. <italic toggle="yes">P</italic> values were 2-tailed; level of significance was .05. All statistical analyses were conducted using R statistical software, version 4.2.1 (R Project for Statistical Computing).</p></sec></sec><sec id="H1-3-AOI230049"><title>Results</title><p>A total of 3395 patients completed an intake visit during the study period, received a buprenorphine prescription within 7 days, and were retained in treatment for 30 or more days (<xref rid="aoi230049t1" ref-type="table">Table 1</xref>). Patients had a mean (SD) age of 38.2 (9.3) years, and were mostly male (54.1%) and non-Hispanic White (81.5%), largely consistent with prior studies of multisite OBOT populations.<sup><xref rid="aoi230049r33" ref-type="bibr">33</xref>,<xref rid="aoi230049r34" ref-type="bibr">34</xref>,<xref rid="aoi230049r35" ref-type="bibr">35</xref></sup> Most patients lived in urban areas (80.3%) and paid for their intake visit out of pocket (74.0%). A total of 1517 (44.7%) patients were ever in network while in care.</p><table-wrap position="float" id="aoi230049t1" orientation="portrait"><label>Table 1. </label><caption><title>Characteristics of Patients Receiving Telehealth-Based Treatment for Opioid Use Disorder With Buprenorphine by Urine Drug Screen Result in First 30 Days (n&#8201;=&#8201;3395)</title></caption><table frame="hsides" rules="groups"><col width="27.09%" span="1"/><col width="15.51%" span="1"/><col width="15.72%" span="1"/><col width="15.01%" span="1"/><col width="16.76%" span="1"/><col width="9.91%" span="1"/><thead><tr><th rowspan="2" valign="top" align="justify" scope="col" colspan="1">Characteristic</th><th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Urine drug screen result in first 30 d of care, No. (%)</th><th rowspan="2" valign="top" align="justify" scope="col" colspan="1"><italic toggle="yes">P</italic> value<xref rid="aoi230049t1n3" ref-type="table-fn"><sup>c</sup></xref></th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">All patients<xref rid="aoi230049t1n1" ref-type="table-fn"><sup>a</sup></xref></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Opioid negative<xref rid="aoi230049t1n2" ref-type="table-fn"><sup>b</sup></xref></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Opioid positive<xref rid="aoi230049t1n2" ref-type="table-fn"><sup>b</sup></xref></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">No urine drug screen<xref rid="aoi230049t1n2" ref-type="table-fn"><sup>b</sup></xref></th></tr></thead><tbody><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1">Total</td><td valign="top" align="justify" rowspan="1" colspan="1">3395</td><td valign="top" align="justify" rowspan="1" colspan="1">2494</td><td valign="top" align="justify" rowspan="1" colspan="1">288</td><td valign="top" align="justify" rowspan="1" colspan="1">613</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="6" valign="top" align="justify" scope="col" rowspan="1">Age at intake visit, y</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> &lt;30</td><td valign="top" align="left" rowspan="1" colspan="1">532 (15.7)</td><td valign="top" align="left" rowspan="1" colspan="1">364 (68.4)</td><td valign="top" align="left" rowspan="1" colspan="1">46 (8.6)</td><td valign="top" align="left" rowspan="1" colspan="1">122 (22.9)</td><td rowspan="5" valign="middle" align="left" colspan="1">.04</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> 30-39</td><td valign="top" align="left" rowspan="1" colspan="1">1567 (46.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1151 (73.5)</td><td valign="top" align="left" rowspan="1" colspan="1">140 (8.9)</td><td valign="top" align="left" rowspan="1" colspan="1">276 (17.6)</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> 40-49</td><td valign="top" align="left" rowspan="1" colspan="1">864 (25.4)</td><td valign="top" align="left" rowspan="1" colspan="1">645 (74.7)</td><td valign="top" align="left" rowspan="1" colspan="1">70 (8.1)</td><td valign="top" align="left" rowspan="1" colspan="1">149 (17.2)</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> 50-59</td><td valign="top" align="left" rowspan="1" colspan="1">319 (9.4)</td><td valign="top" align="left" rowspan="1" colspan="1">239 (74.9)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (8.8)</td><td valign="top" align="left" rowspan="1" colspan="1">52 (16.3)</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> &#8805;60</td><td valign="top" align="left" rowspan="1" colspan="1">108 (3.2)</td><td valign="top" align="left" rowspan="1" colspan="1">90 (83.3)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (3.7)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (13.0)</td></tr><tr><td valign="bottom" colspan="6" align="justify" scope="col" rowspan="1">Gender</td></tr><tr><td valign="bottom" align="justify" scope="row" rowspan="1" colspan="1"> Female</td><td valign="bottom" align="left" rowspan="1" colspan="1">1414 (41.6)</td><td valign="bottom" align="left" rowspan="1" colspan="1">1042 (73.7)</td><td valign="bottom" align="left" rowspan="1" colspan="1">125 (8.8)</td><td valign="bottom" align="left" rowspan="1" colspan="1">247 (17.5)</td><td rowspan="3" valign="middle" align="left" colspan="1">.94</td></tr><tr><td valign="bottom" align="justify" scope="row" rowspan="1" colspan="1"> Male</td><td valign="bottom" align="left" rowspan="1" colspan="1">1835 (54.1)</td><td valign="bottom" align="left" rowspan="1" colspan="1">1346 (73.4)</td><td valign="bottom" align="left" rowspan="1" colspan="1">153 (8.3)</td><td valign="bottom" align="left" rowspan="1" colspan="1">336 (18.3)</td></tr><tr><td valign="bottom" align="justify" scope="row" rowspan="1" colspan="1"> Transgender/nonbinary/other</td><td valign="bottom" align="left" rowspan="1" colspan="1">41 (1.2)</td><td valign="bottom" align="left" rowspan="1" colspan="1">32 (78.0)</td><td valign="bottom" align="left" rowspan="1" colspan="1">3 (7.3)</td><td valign="bottom" align="left" rowspan="1" colspan="1">6 (14.6)</td></tr><tr><td colspan="6" valign="top" align="justify" scope="col" rowspan="1">Race and ethnicity</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> Hispanic/Latino</td><td valign="top" align="left" rowspan="1" colspan="1">217 (6.4)</td><td valign="top" align="left" rowspan="1" colspan="1">142 (65.4)</td><td valign="top" align="left" rowspan="1" colspan="1">21 (9.7)</td><td valign="top" align="left" rowspan="1" colspan="1">54 (24.9)</td><td rowspan="4" valign="middle" align="left" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic African American</td><td valign="top" align="left" rowspan="1" colspan="1">136 (4.0)</td><td valign="top" align="left" rowspan="1" colspan="1">82 (60.3)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (12.5)</td><td valign="top" align="left" rowspan="1" colspan="1">37 (27.2)</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> Non-Hispanic White</td><td valign="top" align="left" rowspan="1" colspan="1">2767 (81.5)</td><td valign="top" align="left" rowspan="1" colspan="1">2080 (75.2)</td><td valign="top" align="left" rowspan="1" colspan="1">229 (8.3)</td><td valign="top" align="left" rowspan="1" colspan="1">458 (16.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic other or multiple races<xref rid="aoi230049t1n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">125 (3.7)</td><td valign="top" align="left" rowspan="1" colspan="1">84 (67.2)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (8.0)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (24.8)</td></tr><tr><td colspan="6" valign="top" align="justify" scope="col" rowspan="1">Urbanicity</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> Urban</td><td valign="top" align="left" rowspan="1" colspan="1">2727 (80.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1965 (72.1)</td><td valign="top" align="left" rowspan="1" colspan="1">245 (9.0)</td><td valign="top" align="left" rowspan="1" colspan="1">517 (19.0)</td><td rowspan="2" valign="middle" align="left" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> Rural</td><td valign="top" align="left" rowspan="1" colspan="1">660 (19.4)</td><td valign="top" align="left" rowspan="1" colspan="1">524 (79.4)</td><td valign="top" align="left" rowspan="1" colspan="1">42 (6.4)</td><td valign="top" align="left" rowspan="1" colspan="1">94 (14.2)</td></tr><tr><td colspan="6" valign="top" align="justify" scope="col" rowspan="1">Payment type at intake visit</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> Cash</td><td valign="top" align="left" rowspan="1" colspan="1">2513 (74.0)</td><td valign="top" align="left" rowspan="1" colspan="1">1821 (72.5)</td><td valign="top" align="left" rowspan="1" colspan="1">198 (7.9)</td><td valign="top" align="left" rowspan="1" colspan="1">494 (19.7)</td><td rowspan="2" valign="middle" align="left" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> Insurance</td><td valign="top" align="left" rowspan="1" colspan="1">882 (26.0)</td><td valign="top" align="left" rowspan="1" colspan="1">673 (76.3)</td><td valign="top" align="left" rowspan="1" colspan="1">90 (10.2)</td><td valign="top" align="left" rowspan="1" colspan="1">119 (13.5)</td></tr></tbody></table><table-wrap-foot><fn id="aoi230049t1n1"><label>
<sup>a</sup>
</label><p>Column percentages.</p></fn><fn id="aoi230049t1n2"><label>
<sup>b</sup>
</label><p>Row percentages.</p></fn><fn id="aoi230049t1n3"><label>
<sup>c</sup>
</label><p><italic toggle="yes">P</italic> values calculated using &#967;<sup>2</sup> tests, with the exception of the <italic toggle="yes">P</italic> value for gender, which was calculated using Fisher exact test due to small cell sizes.</p></fn><fn id="aoi230049t1n4"><label>
<sup>d</sup>
</label><p>Other races include Asian, Native American, and Pacific Islander.</p></fn></table-wrap-foot></table-wrap><p>A total of 2494 patients were opioid negative (73.4%), 288 were opioid positive (8.5%), and 613 (18.1%) did not complete a UDS in the first 30 days of care. Younger patients, patients of racial and ethnic minority groups, those living in urban areas, and those who paid out of pocket were less likely to complete a UDS in the first 30 days of care (<xref rid="aoi230049t1" ref-type="table">Table 1</xref>).</p><p>A total of 2782 of 3395 (81.9%) patients retained for at least 30 days completed a UDS within the first 30 days of care: 1988 of 2210 (90.0%) protocol-adherent patients and 794 of 1185 (67.0%) protocol-nonadherent patients (<xref rid="aoi230049t2" ref-type="table">Table 2</xref>). A total of 2750 of 2817 (97.6%) patients retained for at least 90 days completed a UDS, as did 2307 of 2314 (99.7%) patients retained for at least 180 days. Among patients retained for at least 180 days, the median (IQR) number of UDSs was 3 (3-4), and the median (IQR) time to first UDS was 14 (7-21) days.</p><table-wrap position="float" id="aoi230049t2" orientation="portrait"><label>Table 2. </label><caption><title>Urine Drug Screen Completion Among Patients Receiving Telehealth-Based Treatment for Opioid Use Disorder With Buprenorphine</title></caption><table frame="hsides" rules="groups"><col width="78.64%" span="1"/><col width="21.36%" span="1"/><thead><tr><th valign="top" align="justify" scope="col" rowspan="1" colspan="1">Measure</th><th valign="top" align="justify" scope="col" rowspan="1" colspan="1">Patients, No. (%)</th></tr></thead><tbody><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1">Completed urine drug screen within 30 d<xref rid="aoi230049t2n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2782 (81.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Completed urine drug screen within 30 d, protocol-adherent patients<xref rid="aoi230049t2n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">1988 (90.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Completed urine drug screen within 30 d, protocol-nonadherent patients<xref rid="aoi230049t2n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">794 (67.0)</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1">Completed urine drug screen within 90 d<xref rid="aoi230049t2n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2750 (97.6)</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1">Completed urine drug screen within 180 d<xref rid="aoi230049t2n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">2307 (99.7)</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1">No. of urine drug screens in first 180 d, median (IQR)<xref rid="aoi230049t2n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="justify" rowspan="1" colspan="1">3.0 (3.0-4.0)</td></tr></tbody></table><table-wrap-foot><fn id="aoi230049t2n1"><label>
<sup>a</sup>
</label><p>Percentage calculated among all 3395 patients.</p></fn><fn id="aoi230049t2n2"><label>
<sup>b</sup>
</label><p>Percentage calculated among 2210 protocol-adherent patients.</p></fn><fn id="aoi230049t2n3"><label>
<sup>c</sup>
</label><p>Percentage calculated among 1185 protocol-nonadherent patients.</p></fn><fn id="aoi230049t2n4"><label>
<sup>d</sup>
</label><p>Percentage calculated among 2817 patients retained for at least 90 days.</p></fn><fn id="aoi230049t2n5"><label>
<sup>e</sup>
</label><p>Percentage and median calculated among 2314 patients retained for at least 180 days.</p></fn></table-wrap-foot></table-wrap><p>We observed variation in rates of UDS completion across clinicians and months in care, which is presented in the <xref rid="aoi230049f1" ref-type="fig">Figure</xref> and eTable 2 in <xref rid="note-AOI230049-1-s" ref-type="supplementary-material">Supplement 1</xref>.</p><fig position="float" id="aoi230049f1" fig-type="figure" orientation="portrait"><label>Figure. </label><caption><title>Clinician Rates of Completed Urine Drug Screenings (UDS) per Patient-Month, by Month in Care</title><p>The horizontal bar inside the boxes indicates the median, and the lower and upper ends of the boxes are the first and third quartiles. Lower whisker extends to the smallest value no further than 1.5&#8201;&#215;&#8201;IQR from the 25th percentile value, and upper whisker extends to the largest value no further than 1.5&#8201;&#215;&#8201;IQR from the 75th percentile value; shaded circles indicate outlier data points.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jamahealthforum-e232247-g001.jpg"/></fig><p>Among 2782 patients with a baseline UDS, 96.1% screened positive for buprenorphine, 9.5% for opioids (5.8% for fentanyl, 0.8% for methadone, 2.3% for oxycodone, 0.6% for tramadol, 2.2% for other opioids), 4.9% for methamphetamine, 4.3% for cocaine, 9.2% for benzodiazepines, 10.1% for amphetamines, 12.8% for alcohol, and 39.3% for cannabis (data not shown).</p><p>Among 1754 patients retained for 180 days and with both a baseline and follow-up UDS (38% of those with a baseline UDS), there was an increase in the positivity rate for buprenorphine (from 96.9% to 98.4%, <italic toggle="yes">P</italic>&#8201;=&#8201;.004) and a decrease in the positivity rate for opioids (from 7.9% to 3.3%, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001), cocaine (from 3.4% to 2.2%, <italic toggle="yes">P</italic>&#8201;=&#8201;.008), and benzodiazepines (from 8.8% to 6.6%, <italic toggle="yes">P</italic>&#8201;=&#8201;.002) (<xref rid="aoi230049t3" ref-type="table">Table 3</xref>). Results from sensitivity analyses that defined follow-up UDSs within 30 days (before or after) (eTable 3 in <xref rid="note-AOI230049-1-s" ref-type="supplementary-material">Supplement 1</xref>) and 90 days (before or after) (eTable 4 in <xref rid="note-AOI230049-1-s" ref-type="supplementary-material">Supplement 1</xref>) of 180 days after starting treatment were largely consistent with the primary definition using 60 days (before or after). Patients included in the baseline/follow-up UDS analysis had a higher baseline positivity rate for buprenorphine and lower baseline positivity rates for opioids, methamphetamine, and cocaine than patients who did not have follow-up UDS data available (eTable 5 in <xref rid="note-AOI230049-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p><table-wrap position="float" id="aoi230049t3" orientation="portrait"><label>Table 3. </label><caption><title>Urine Drug Screen Results During Baseline (First Urine Drug Screen Within 30 Days of Initiating Treatment) and Follow-Up (Closest Urine Drug Screen to 180 Days After Initiating Treatment, Between 120 and 240 Days After Initiating Treatment) (n&#8201;=&#8201;1754)</title></caption><table frame="hsides" rules="groups"><col width="32.16%" span="1"/><col width="25.51%" span="1"/><col width="25.51%" span="1"/><col width="16.82%" span="1"/><thead><tr><th rowspan="2" valign="top" align="justify" scope="col" colspan="1">Drug</th><th colspan="2" valign="top" align="justify" scope="colgroup" rowspan="1">No. (%)</th><th rowspan="2" valign="top" align="justify" scope="col" colspan="1"><italic toggle="yes">P</italic> value<xref rid="aoi230049t3n1" ref-type="table-fn"><sup>a</sup></xref></th></tr><tr><th valign="top" colspan="1" align="justify" scope="colgroup" rowspan="1">Baseline</th><th valign="top" align="justify" scope="col" rowspan="1" colspan="1">Follow-up</th></tr></thead><tbody><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1">Buprenorphine</td><td valign="top" align="left" rowspan="1" colspan="1">1699 (96.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1726 (98.4)</td><td valign="top" align="justify" rowspan="1" colspan="1">.004</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1">Opioids</td><td valign="top" align="left" rowspan="1" colspan="1">138 (7.9)</td><td valign="top" align="left" rowspan="1" colspan="1">58 (3.3)</td><td valign="top" align="justify" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> Fentanyl</td><td valign="top" align="left" rowspan="1" colspan="1">76 (4.3)</td><td valign="top" align="left" rowspan="1" colspan="1">29 (1.7)</td><td valign="top" align="justify" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> Methadone</td><td valign="top" align="left" rowspan="1" colspan="1">15 (0.9)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (0.2)</td><td valign="top" align="justify" rowspan="1" colspan="1">.01</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> Oxycodone</td><td valign="top" align="left" rowspan="1" colspan="1">36 (2.1)</td><td valign="top" align="left" rowspan="1" colspan="1">20 (1.1)</td><td valign="top" align="justify" rowspan="1" colspan="1">.02</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> Tramadol</td><td valign="top" align="left" rowspan="1" colspan="1">8 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (0.3)</td><td valign="top" align="justify" rowspan="1" colspan="1">.77</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1"> Other opioids</td><td valign="top" align="left" rowspan="1" colspan="1">33 (1.9)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (0.6)</td><td valign="top" align="justify" rowspan="1" colspan="1">&lt;.001</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1">Methamphetamine</td><td valign="top" align="left" rowspan="1" colspan="1">66 (3.8)</td><td valign="top" align="left" rowspan="1" colspan="1">54 (3.1)</td><td valign="top" align="justify" rowspan="1" colspan="1">.14</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1">Cocaine</td><td valign="top" align="left" rowspan="1" colspan="1">60 (3.4)</td><td valign="top" align="left" rowspan="1" colspan="1">38 (2.2)</td><td valign="top" align="justify" rowspan="1" colspan="1">.008</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1">Benzodiazepines</td><td valign="top" align="left" rowspan="1" colspan="1">155 (8.8)</td><td valign="top" align="left" rowspan="1" colspan="1">116 (6.6)</td><td valign="top" align="justify" rowspan="1" colspan="1">.002</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1">Amphetamines</td><td valign="top" align="left" rowspan="1" colspan="1">164 (9.4)</td><td valign="top" align="left" rowspan="1" colspan="1">186 (10.6)</td><td valign="top" align="justify" rowspan="1" colspan="1">.095</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1">Alcohol</td><td valign="top" align="left" rowspan="1" colspan="1">214 (12.2)</td><td valign="top" align="left" rowspan="1" colspan="1">213 (12.1)</td><td valign="top" align="justify" rowspan="1" colspan="1">1.00</td></tr><tr><td valign="top" align="justify" scope="row" rowspan="1" colspan="1">Cannabis</td><td valign="top" align="left" rowspan="1" colspan="1">680 (38.8)</td><td valign="top" align="left" rowspan="1" colspan="1">654 (37.3)</td><td valign="top" align="justify" rowspan="1" colspan="1">.17</td></tr></tbody></table><table-wrap-foot><fn id="aoi230049t3n1"><label>
<sup>a</sup>
</label><p><italic toggle="yes">P</italic> values calculated using McNemar tests.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H1-4-AOI230049"><title>Discussion</title><p>We found that most patients completed a UDS in the first 30 days of care, and an overwhelming majority completed one within the first 90 days of care, suggesting that drug testing was mostly feasible to conduct over an exclusively telehealth treatment platform without requiring any in-person visits. We also found low rates of opioid use across all time points in care, with additional declines from early to later points in care, which suggests that buprenorphine delivered in TBOT settings is an effective treatment for OUD, and is consistent with favorable retention outcomes observed in this and other TBOT settings.<sup><xref rid="aoi230049r27" ref-type="bibr">27</xref>,<xref rid="aoi230049r28" ref-type="bibr">28</xref>,<xref rid="aoi230049r36" ref-type="bibr">36</xref>,<xref rid="aoi230049r37" ref-type="bibr">37</xref>,<xref rid="aoi230049r38" ref-type="bibr">38</xref></sup> To our knowledge, this is the first study characterizing UDS administration and results in an exclusively TBOT setting, an important step toward identifying the appropriate role and optimal processes for UDS in remote care settings.</p><p>Although TBOT has demonstrated the potential to extend treatment access to underserved areas,<sup><xref rid="aoi230049r38" ref-type="bibr">38</xref>,<xref rid="aoi230049r39" ref-type="bibr">39</xref></sup> our findings that early UDS completion varied across demographic subgroups suggests that further study of UDS in remote care settings is warranted. As telehealth-based care has expanded in recent years, there have been concerns that the &#8220;digital divide&#8221; (ie, unequal access to digital technology and Wi-Fi that disproportionately affects marginalized populations) could exacerbate existing disparities related to health care access.<sup><xref rid="aoi230049r40" ref-type="bibr">40</xref>,<xref rid="aoi230049r41" ref-type="bibr">41</xref></sup> It is thus important for TBOT platforms to consider the complex interplay between clinical suitability for remote care and socioeconomic and digital barriers, aiming to address the latter while not compromising on the former. However, the low rates of unexpected results and declining drug use observed over the first 6 months of care offer further evidence that buprenorphine delivered in TBOT settings is an effective treatment for OUD and suggest that patient-centered drug testing is effective, consistent with prior studies in other settings.<sup><xref rid="aoi230049r42" ref-type="bibr">42</xref></sup></p><sec id="H2-5-AOI230049"><title>Limitations</title><p>There are several limitations to our analyses that require further study. First, the rate of opioid positivity in our sample was substantially lower than that observed in in-person OBOT settings both early in care and at 6 months,<sup><xref rid="aoi230049r43" ref-type="bibr">43</xref></sup> which raises questions about how these populations may differ. Also, if patients not completing a UDS were more likely to use opioids (ie, if clinicians were less likely to administer UDS to patients who spoke openly about recent drug use), the rates observed may underestimate the true rates of opioid positivity. Second, patients in TBOT settings and those in our sample in particular may not be representative of all patients with OUD. Specifically, our sample excluded patients requiring a higher level of care and comprised mostly patients residing in New York and Pennsylvania and paying for care out of pocket and thus may not be generalizable to other patient segments. Third, it is possible that remote UDS as described in this study could be more vulnerable to sample tampering than in-person UDS and thus contribute to the low rates of unexpected results. However, we implemented several strategies to mitigate the risk of sample tampering and faked results, including synchronous administration during visits and real-time sample verification and interpretation. Further, the persistence of cannabis positivity, around 38% across time points while in care, replicates prevalence of cannabis use during a similar time period in a prior multisite OBOT study with in-person UDS administration<sup><xref rid="aoi230049r43" ref-type="bibr">43</xref></sup> and is also theoretically inconsistent with patients regularly procuring substance-negative urine elsewhere to covertly substitute samples. Moreover, while it may seem that in-person UDS samples are largely impervious to the possibility of tampering, 1 study found that 18% of a sample of patients receiving in-person OBOT care submitted urine samples with evidence of tampering.<sup><xref rid="aoi230049r44" ref-type="bibr">44</xref></sup> This may be true irrespective of treatment setting, and further research is needed to understand whether the reliability of UDS in remote settings is any different than in in-person settings.</p></sec></sec><sec id="H1-5-AOI230049"><title>Conclusions</title><p>There has been a seminal shift in the National Drug Control Strategy and White House prerogatives for responding to the opioid crisis, notably expanding harm reduction services and removing the Drug Enforcement Administration&#8217;s X-waiver requirement for buprenorphine prescribers as of January 2023. In the context of ongoing policy debates over responding to the opioid crisis and allowances for telehealth modalities,<sup><xref rid="aoi230049r41" ref-type="bibr">41</xref>,<xref rid="aoi230049r45" ref-type="bibr">45</xref>,<xref rid="aoi230049r46" ref-type="bibr">46</xref></sup> removing barriers to buprenorphine access via low-threshold or &#8220;minimally invasive&#8221; care settings,<sup><xref rid="aoi230049r47" ref-type="bibr">47</xref></sup> aligned with improving equity, has become central.<sup><xref rid="aoi230049r48" ref-type="bibr">48</xref>,<xref rid="aoi230049r49" ref-type="bibr">49</xref></sup> Largely due to COVID-19 regulatory reforms, the rapid expansion of telehealth for mental health and addiction treatment has bypassed long-standing requirements for initial in-person visits before prescribing controlled substances.<sup><xref rid="aoi230049r50" ref-type="bibr">50</xref></sup> Typically, TBOT models, similar to emergency department&#8211;initiated medication &#8220;bridge clinics,&#8221; have many fewer requirements&#8212;such as group attendance, frequent drug testing, and counseling&#8212;than historic standards of care, and yet retention and adherence outcomes appear to be equivalent and possibly superior to those of traditional care settings.<sup><xref rid="aoi230049r27" ref-type="bibr">27</xref>,<xref rid="aoi230049r28" ref-type="bibr">28</xref>,<xref rid="aoi230049r36" ref-type="bibr">36</xref>,<xref rid="aoi230049r37" ref-type="bibr">37</xref>,<xref rid="aoi230049r38" ref-type="bibr">38</xref></sup> This cohort study&#8217;s findings that remotely administered UDS was feasible and associated with low rates of unexpected results that improved with time in care are consistent with the premise that long-standing and stringent requirements (eg, requiring in-person visits, frequent drug testing)<sup><xref rid="aoi230049r51" ref-type="bibr">51</xref></sup> for being prescribed buprenorphine for OUD can be relaxed without jeopardizing the quality or safety of care for many patients.</p></sec></body><back><ref-list id="REF-AOI230049"><title>References</title><ref id="aoi230049r1"><label>1</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Olfson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>VS</given-names></string-name>, <string-name name-style="western"><surname>Schoenbaum</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>King</surname><given-names>M</given-names></string-name></person-group>. <article-title>Trends in buprenorphine treatment in the United States, 2009-2018</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>323</volume>(<issue>3</issue>):<fpage>276</fpage>-<lpage>277</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2019.18913</pub-id><pub-id pub-id-type="pmid">31961408</pub-id><pub-id pub-id-type="pmcid">PMC6990679</pub-id></mixed-citation></ref><ref id="aoi230049r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Keyes</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Rutherford</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hamilton</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? using multiplier approaches to estimate prevalence for an unknown population size</article-title>. <source>Drug Alcohol Depend Rep</source>. <year>2022</year>;<volume>3</volume>:<elocation-id>100052</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.dadr.2022.100052</pub-id><pub-id pub-id-type="pmid">35783994</pub-id><pub-id pub-id-type="pmcid">PMC9248998</pub-id></mixed-citation></ref><ref id="aoi230049r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Wen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Borders</surname><given-names>TF</given-names></string-name>, <string-name name-style="western"><surname>Cummings</surname><given-names>JR</given-names></string-name></person-group>. <article-title>Trends in buprenorphine prescribing by physician specialty</article-title>. <source>Health Aff (Millwood)</source>. <year>2019</year>;<volume>38</volume>(<issue>1</issue>):<fpage>24</fpage>-<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.2018.05145</pub-id><pub-id pub-id-type="pmid">30615523</pub-id></mixed-citation></ref><ref id="aoi230049r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Creedon</surname><given-names>TB</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Schuman-Olivier</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Trends in buprenorphine prescribing for opioid use disorder by psychiatrists in the US from 2003 to 2021</article-title>. <source>JAMA Health Forum</source>. <year>2023</year>;<volume>4</volume>(<issue>4</issue>):<elocation-id>e230221</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamahealthforum.2023.0221</pub-id><pub-id pub-id-type="pmid">37027166</pub-id><pub-id pub-id-type="pmcid">PMC10082400</pub-id></mixed-citation></ref><ref id="aoi230049r5"><label>5</label><mixed-citation publication-type="book"><person-group><collab>National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder</collab>; <string-name name-style="western"><surname>Leshner</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Mancher</surname><given-names>M</given-names></string-name></person-group>, eds. <source>Medications for Opioid Use Disorder Save Lives</source>. <publisher-name>National Academies Press</publisher-name>; <year>2019</year>.<pub-id pub-id-type="pmid">30896911</pub-id></mixed-citation></ref><ref id="aoi230049r6"><label>6</label><mixed-citation publication-type="webpage"><person-group><collab>Office of the Secretary, Department of Health and Human Services</collab></person-group>. Practice guidelines for the administration of buprenorphine for treating opioid use disorder. Published online April 28, 2021. Accessed December 5, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.federalregister.gov/documents/2021/04/28/2021-08961/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder" ext-link-type="uri">https://www.federalregister.gov/documents/2021/04/28/2021-08961/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder</ext-link></mixed-citation></ref><ref id="aoi230049r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Sordo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Barrio</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bravo</surname><given-names>MJ</given-names></string-name>, <etal/></person-group>. <article-title>Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies</article-title>. <source>BMJ</source>. <year>2017</year>;<volume>357</volume>:<fpage>j1550</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.j1550</pub-id><pub-id pub-id-type="pmid">28446428</pub-id><pub-id pub-id-type="pmcid">PMC5421454</pub-id></mixed-citation></ref><ref id="aoi230049r8"><label>8</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Santo</surname><given-names>T</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Clark</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hickman</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis</article-title>. <source>JAMA Psychiatry</source>. <year>2021</year>;<volume>78</volume>(<issue>9</issue>):<fpage>979</fpage>-<lpage>993</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2021.0976</pub-id><pub-id pub-id-type="pmid">34076676</pub-id><pub-id pub-id-type="pmcid">PMC8173472</pub-id></mixed-citation></ref><ref id="aoi230049r9"><label>9</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Bentzley</surname><given-names>BS</given-names></string-name>, <string-name name-style="western"><surname>Barth</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Back</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Book</surname><given-names>SW</given-names></string-name></person-group>. <article-title>Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes</article-title>. <source>J Subst Abuse Treat</source>. <year>2015</year>;<volume>52</volume>:<fpage>48</fpage>-<lpage>57</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2014.12.011</pub-id><pub-id pub-id-type="pmid">25601365</pub-id><pub-id pub-id-type="pmcid">PMC4382404</pub-id></mixed-citation></ref><ref id="aoi230049r10"><label>10</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Liebschutz</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ross-Degnan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wharam</surname><given-names>JF</given-names></string-name></person-group>. <article-title>Opioid prescribing after nonfatal overdose and association with repeated overdose: a cohort study</article-title>. <source>Ann Intern Med</source>. <year>2016</year>;<volume>164</volume>(<issue>1</issue>):<fpage>1</fpage>-<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M15-0038</pub-id><pub-id pub-id-type="pmid">26720742</pub-id></mixed-citation></ref><ref id="aoi230049r11"><label>11</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Incze</surname><given-names>MA</given-names></string-name></person-group>. <article-title>Reassessing the role of routine urine drug screening in opioid use disorder treatment</article-title>. <source>JAMA Intern Med</source>. <year>2021</year>;<volume>181</volume>(<issue>10</issue>):<fpage>1282</fpage>-<lpage>1283</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamainternmed.2021.4109</pub-id><pub-id pub-id-type="pmid">34338713</pub-id></mixed-citation></ref><ref id="aoi230049r12"><label>12</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Bagley</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Winter</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Opioid and cocaine use among primary care patients on buprenorphine&#8212;self-report and urine drug tests</article-title>. <source>Drug Alcohol Depend</source>. <year>2018</year>;<volume>192</volume>:<fpage>245</fpage>-<lpage>249</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.08.010</pub-id><pub-id pub-id-type="pmid">30290291</pub-id><pub-id pub-id-type="pmcid">PMC6291245</pub-id></mixed-citation></ref><ref id="aoi230049r13"><label>13</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Ceasar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zamora</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>Primary care providers&#8217; experiences with urine toxicology tests to manage prescription opioid misuse and substance use among chronic noncancer pain patients in safety net health care settings</article-title>. <source>Subst Abus</source>. <year>2016</year>;<volume>37</volume>(<issue>1</issue>):<fpage>154</fpage>-<lpage>160</lpage>. doi:<pub-id pub-id-type="doi">10.1080/08897077.2015.1132293</pub-id><pub-id pub-id-type="pmid">26682471</pub-id><pub-id pub-id-type="pmcid">PMC4823143</pub-id></mixed-citation></ref><ref id="aoi230049r14"><label>14</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Gertner</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Clare</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Powell</surname><given-names>BJ</given-names></string-name>, <etal/></person-group>. <article-title>A mixed methods study of provider factors in buprenorphine treatment retention</article-title>. <source>Int J Drug Policy</source>. <year>2022</year>;<volume>105</volume>:<elocation-id>103715</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugpo.2022.103715</pub-id><pub-id pub-id-type="pmid">35533634</pub-id><pub-id pub-id-type="pmcid">PMC9246997</pub-id></mixed-citation></ref><ref id="aoi230049r15"><label>15</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Potter</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Dreifuss</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Marino</surname><given-names>EN</given-names></string-name>, <etal/></person-group>. <article-title>The multi-site prescription opioid addiction treatment study: 18-month outcomes</article-title>. <source>J Subst Abuse Treat</source>. <year>2015</year>;<volume>48</volume>(<issue>1</issue>):<fpage>62</fpage>-<lpage>69</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2014.07.009</pub-id><pub-id pub-id-type="pmid">25189089</pub-id><pub-id pub-id-type="pmcid">PMC4250351</pub-id></mixed-citation></ref><ref id="aoi230049r16"><label>16</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Sohn</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Talbert</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Oser</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Freeman</surname><given-names>PR</given-names></string-name></person-group>. <article-title>Trends in urine drug monitoring among persons receiving long-term opioids and persons with opioid use disorder in the United States</article-title>. <source>Pain Physician</source>. <year>2021</year>;<volume>24</volume>(<issue>2</issue>):<fpage>E249</fpage>-<lpage>E256</lpage>.<pub-id pub-id-type="pmid">33740362</pub-id><pub-id pub-id-type="pmcid">PMC8195321</pub-id></mixed-citation></ref><ref id="aoi230049r17"><label>17</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Khatri</surname><given-names>UG</given-names></string-name>, <string-name name-style="western"><surname>Aronowitz</surname><given-names>SV</given-names></string-name></person-group>. <article-title>Considering the harms of our habits: the reflexive urine drug screen in opioid use disorder treatment</article-title>. <source>J Subst Abuse Treat</source>. <year>2021</year>;<volume>123</volume>:<elocation-id>108258</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2020.108258</pub-id><pub-id pub-id-type="pmid">33358617</pub-id><pub-id pub-id-type="pmcid">PMC9759699</pub-id></mixed-citation></ref><ref id="aoi230049r18"><label>18</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>McEachern</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Adye-White</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Priest</surname><given-names>KC</given-names></string-name>, <etal/></person-group>. <article-title>Lacking evidence for the association between frequent urine drug screening and health outcomes of persons on opioid agonist therapy</article-title>. <source>Int J Drug Policy</source>. <year>2019</year>;<volume>64</volume>:<fpage>30</fpage>-<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugpo.2018.08.006</pub-id><pub-id pub-id-type="pmid">30551003</pub-id><pub-id pub-id-type="pmcid">PMC6500449</pub-id></mixed-citation></ref><ref id="aoi230049r19"><label>19</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Dupouy</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>M&#233;mier</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Catala</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lavit</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Oustric</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lapeyre-Mestre</surname><given-names>M</given-names></string-name></person-group>. <article-title>Does urine drug abuse screening help for managing patients? a systematic review</article-title>. <source>Drug Alcohol Depend</source>. <year>2014</year>;<volume>136</volume>:<fpage>11</fpage>-<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2013.12.009</pub-id><pub-id pub-id-type="pmid">24417964</pub-id></mixed-citation></ref><ref id="aoi230049r20"><label>20</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Monwell</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>B&#252;low</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bj&#246;rn</surname><given-names>J</given-names></string-name></person-group>. <article-title>The pros and cons of supervised urine tests in opioid replacement therapy: a study of patients&#8217; experiences</article-title>. <source>Heroin Addict Relat Clin Probl</source>. <year>2018</year>;<volume>20</volume>(<issue>6</issue>):<fpage>5</fpage>-<lpage>15</lpage>.</mixed-citation></ref><ref id="aoi230049r21"><label>21</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Morin</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Dabous</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Vojtesek</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Marsh</surname><given-names>D</given-names></string-name></person-group>. <article-title>Evaluating the association between urine drug screening frequency and retention in opioid agonist treatment in Ontario, Canada: a retrospective cohort study</article-title>. <source>BMJ Open</source>. <year>2022</year>;<volume>12</volume>(<issue>10</issue>):<elocation-id>e060857</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmjopen-2022-060857</pub-id><pub-id pub-id-type="pmid">36223960</pub-id><pub-id pub-id-type="pmcid">PMC9562722</pub-id></mixed-citation></ref><ref id="aoi230049r22"><label>22</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jarvis</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hurford</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Appropriate use of drug testing in clinical addiction medicine</article-title>. <source>J Addict Med</source>. <year>2017</year>;<volume>11</volume>(<issue>3</issue>):<fpage>163</fpage>-<lpage>173</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000000323</pub-id><pub-id pub-id-type="pmid">28557958</pub-id></mixed-citation></ref><ref id="aoi230049r23"><label>23</label><mixed-citation publication-type="webpage"><person-group><collab>New York State Office of Addiction Services and Supports</collab></person-group>. Guidance on toxicology use in OASAS certified programs. Published online November 24, 2021. Accessed June 25, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://oasas.ny.gov/system/files/documents/2021/11/oasas-toxicology-guidance_0.pdf" ext-link-type="uri">https://oasas.ny.gov/system/files/documents/2021/11/oasas-toxicology-guidance_0.pdf</ext-link></mixed-citation></ref><ref id="aoi230049r24"><label>24</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Becker</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Starrels</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Heo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Weiner</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>BJ</given-names></string-name></person-group>. <article-title>Racial differences in primary care opioid risk reduction strategies</article-title>. <source>Ann Fam Med</source>. <year>2011</year>;<volume>9</volume>(<issue>3</issue>):<fpage>219</fpage>-<lpage>225</lpage>. doi:<pub-id pub-id-type="doi">10.1370/afm.1242</pub-id><pub-id pub-id-type="pmid">21555749</pub-id><pub-id pub-id-type="pmcid">PMC3090430</pub-id></mixed-citation></ref><ref id="aoi230049r25"><label>25</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hausmann</surname><given-names>LRM</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Kwoh</surname><given-names>KC</given-names></string-name></person-group>. <article-title>Racial disparities in the monitoring of patients on chronic opioid therapy</article-title>. <source>Pain</source>. <year>2013</year>;<volume>154</volume>(<issue>1</issue>):<fpage>46</fpage>-<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pain.2012.07.034</pub-id><pub-id pub-id-type="pmid">23273103</pub-id></mixed-citation></ref><ref id="aoi230049r26"><label>26</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lin</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Fernandez</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Bonar</surname><given-names>EE</given-names></string-name></person-group>. <article-title>Telehealth for substance-using populations in the age of coronavirus disease 2019: recommendations to enhance adoption</article-title>. <source>JAMA Psychiatry</source>. <year>2020</year>;<volume>77</volume>(<issue>12</issue>):<fpage>1209</fpage>-<lpage>1210</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2020.1698</pub-id><pub-id pub-id-type="pmid">32609317</pub-id><pub-id pub-id-type="pmcid">PMC8108064</pub-id></mixed-citation></ref><ref id="aoi230049r27"><label>27</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Jones</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Shoff</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hodges</surname><given-names>K</given-names></string-name>, <etal/></person-group>. <article-title>Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among Medicare beneficiaries before and during the COVID-19 pandemic</article-title>. <source>JAMA Psychiatry</source>. <year>2022</year>;<volume>79</volume>(<issue>10</issue>):<fpage>981</fpage>-<lpage>992</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2022.2284</pub-id><pub-id pub-id-type="pmid">36044198</pub-id><pub-id pub-id-type="pmcid">PMC9434479</pub-id></mixed-citation></ref><ref id="aoi230049r28"><label>28</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Frost</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>LA</given-names></string-name></person-group>. <article-title>Use of and retention on video, telephone, and in-person buprenorphine treatment for opioid use disorder during the COVID-19 pandemic</article-title>. <source>JAMA Netw Open</source>. <year>2022</year>;<volume>5</volume>(<issue>10</issue>):<elocation-id>e2236298</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2022.36298</pub-id><pub-id pub-id-type="pmid">36223118</pub-id><pub-id pub-id-type="pmcid">PMC9557869</pub-id></mixed-citation></ref><ref id="aoi230049r29"><label>29</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hughes</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Verrastro</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Fusco</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Ostrach</surname><given-names>B</given-names></string-name></person-group>. <article-title>An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic</article-title>. <source>J Rural Health</source>. <year>2021</year>;<volume>37</volume>(<issue>3</issue>):<fpage>467</fpage>-<lpage>472</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jrh.12570</pub-id><pub-id pub-id-type="pmid">33720447</pub-id><pub-id pub-id-type="pmcid">PMC8250742</pub-id></mixed-citation></ref><ref id="aoi230049r30"><label>30</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Huskamp</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Busch</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Uscher-Pines</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Barnett</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Riedel</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mehrotra</surname><given-names>A</given-names></string-name></person-group>. <article-title>Treatment of opioid use disorder among commercially insured patients in the context of the COVID-19 pandemic</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>324</volume>(<issue>23</issue>):<fpage>2440</fpage>-<lpage>2442</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.21512</pub-id><pub-id pub-id-type="pmid">33320214</pub-id><pub-id pub-id-type="pmcid">PMC7739126</pub-id></mixed-citation></ref><ref id="aoi230049r31"><label>31</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Uscher-Pines</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sousa</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Raja</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mehrotra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Barnett</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Huskamp</surname><given-names>HA</given-names></string-name></person-group>. <article-title>Treatment of opioid use disorder during COVID-19: experiences of clinicians transitioning to telemedicine</article-title>. <source>J Subst Abuse Treat</source>. <year>2020</year>;<volume>118</volume>:<elocation-id>108124</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2020.108124</pub-id><pub-id pub-id-type="pmid">32893047</pub-id><pub-id pub-id-type="pmcid">PMC7456454</pub-id></mixed-citation></ref><ref id="aoi230049r32"><label>32</label><mixed-citation publication-type="webpage"><person-group><collab>Economic Research Service, US Dept of Agriculture</collab></person-group>. Rural-urban continuum codes. Published online December 10, 2020. Accessed December 20, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ers.usda.gov/data-products/rural-urban-continuum-codes.aspx" ext-link-type="uri">https://www.ers.usda.gov/data-products/rural-urban-continuum-codes.aspx</ext-link></mixed-citation></ref><ref id="aoi230049r33"><label>33</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Samples</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Olfson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Crystal</surname><given-names>S</given-names></string-name></person-group>. <article-title>Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees</article-title>. <source>J Subst Abuse Treat</source>. <year>2018</year>;<volume>95</volume>:<fpage>9</fpage>-<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2018.09.001</pub-id><pub-id pub-id-type="pmid">30352671</pub-id><pub-id pub-id-type="pmcid">PMC6354252</pub-id></mixed-citation></ref><ref id="aoi230049r34"><label>34</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Williams</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Samples</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Crystal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Olfson</surname><given-names>M</given-names></string-name></person-group>. <article-title>Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder</article-title>. <source>Am J Psychiatry</source>. <year>2020</year>;<volume>177</volume>(<issue>2</issue>):<fpage>117</fpage>-<lpage>124</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.ajp.2019.19060612</pub-id><pub-id pub-id-type="pmid">31786933</pub-id><pub-id pub-id-type="pmcid">PMC7002204</pub-id></mixed-citation></ref><ref id="aoi230049r35"><label>35</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Manhapra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Agbese</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Leslie</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Rosenheck</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults</article-title>. <source>Psychiatr Serv</source>. <year>2018</year>;<volume>69</volume>(<issue>7</issue>):<fpage>768</fpage>-<lpage>776</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.ps.201700363</pub-id><pub-id pub-id-type="pmid">29656707</pub-id></mixed-citation></ref><ref id="aoi230049r36"><label>36</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lin</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Frost</surname><given-names>MC</given-names></string-name></person-group>. <article-title>Impact of COVID-19 telehealth policy changes on buprenorphine treatment for opioid use disorder</article-title>. <source>Am J Psychiatry</source>. <year>2022</year>;<volume>179</volume>(<issue>10</issue>):<fpage>740</fpage>-<lpage>747</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.ajp.21111141</pub-id><pub-id pub-id-type="pmid">35899380</pub-id><pub-id pub-id-type="pmcid">PMC9529783</pub-id></mixed-citation></ref><ref id="aoi230049r37"><label>37</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Weintraub</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Greenblatt</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Outcomes for patients receiving telemedicine-delivered medication-based treatment for opioid use disorder: a retrospective chart review</article-title>. <source>Heroin Addict Relat Clin Probl</source>. <year>2021</year>;<volume>23</volume>(<issue>2</issue>):<fpage>5</fpage>-<lpage>12</lpage>.<pub-id pub-id-type="pmid">33551692</pub-id><pub-id pub-id-type="pmcid">PMC7861202</pub-id></mixed-citation></ref><ref id="aoi230049r38"><label>38</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Williams</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Aronowitz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gallagher</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Behar</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Bisaga</surname><given-names>A</given-names></string-name></person-group>. <article-title>A virtual-first telehealth treatment model for opioid use disorder</article-title>. <source>J Gen Intern Med</source>. <year>2023</year>;<volume>38</volume>(<issue>3</issue>):<fpage>814</fpage>-<lpage>816</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-022-07955-x</pub-id><pub-id pub-id-type="pmid">36456841</pub-id><pub-id pub-id-type="pmcid">PMC9714767</pub-id></mixed-citation></ref><ref id="aoi230049r39"><label>39</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Weintraub</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Greenblatt</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Himelhoch</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Welsh</surname><given-names>C</given-names></string-name></person-group>. <article-title>Expanding access to buprenorphine treatment in rural areas with the use of telemedicine</article-title>. <source>Am J Addict</source>. <year>2018</year>;<volume>27</volume>(<issue>8</issue>):<fpage>612</fpage>-<lpage>617</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ajad.12805</pub-id><pub-id pub-id-type="pmid">30265425</pub-id></mixed-citation></ref><ref id="aoi230049r40"><label>40</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Eyrich</surname><given-names>NW</given-names></string-name>, <string-name name-style="western"><surname>Andino</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Fessell</surname><given-names>DP</given-names></string-name></person-group>. <article-title>Bridging the digital divide to avoid leaving the most vulnerable behind</article-title>. <source>JAMA Surg</source>. <year>2021</year>;<volume>156</volume>(<issue>8</issue>):<fpage>703</fpage>-<lpage>704</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamasurg.2021.1143</pub-id><pub-id pub-id-type="pmid">33769441</pub-id></mixed-citation></ref><ref id="aoi230049r41"><label>41</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Uscher-Pines</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sousa</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Predmore</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ober</surname><given-names>A</given-names></string-name></person-group>. The doctor will call me maybe: the uncertain future of audio-only visits and why we need them to address disparities. Health Affairs Forefront. Published online March 3, 2021. Accessed June 25, 2023. doi:<pub-id pub-id-type="doi">10.1377/forefront.20210225.26462</pub-id></mixed-citation></ref><ref id="aoi230049r42"><label>42</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Sobel</surname><given-names>HG</given-names></string-name>, <string-name name-style="western"><surname>Warrington</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Francis-Fath</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Crocker</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Berger</surname><given-names>CA</given-names></string-name></person-group>. <article-title>A descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting</article-title>. <source>Addict Sci Clin Pract</source>. <year>2021</year>;<volume>16</volume>(<issue>1</issue>):<fpage>59</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13722-021-00264-4</pub-id><pub-id pub-id-type="pmid">34593036</pub-id><pub-id pub-id-type="pmcid">PMC8482571</pub-id></mixed-citation></ref><ref id="aoi230049r43"><label>43</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Williams</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Mauro</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>T</given-names></string-name>, <etal/></person-group>. <article-title>Non-prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder</article-title>. <source>J Subst Abuse Treat</source>. <year>2022</year>;<volume>139</volume>:<elocation-id>108770</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2022.108770</pub-id><pub-id pub-id-type="pmid">35337715</pub-id><pub-id pub-id-type="pmcid">PMC9187606</pub-id></mixed-citation></ref><ref id="aoi230049r44"><label>44</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Accurso</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>McNeely</surname><given-names>J</given-names></string-name></person-group>. <article-title>High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio</article-title>. <source>J Subst Abuse Treat</source>. <year>2017</year>;<volume>83</volume>:<fpage>62</fpage>-<lpage>67</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2017.10.002</pub-id><pub-id pub-id-type="pmid">29129197</pub-id></mixed-citation></ref><ref id="aoi230049r45"><label>45</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Poorman</surname><given-names>E</given-names></string-name></person-group>. <article-title>The number needed to prescribe&#8212;what would it take to expand access to buprenorphine?</article-title><source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>(<issue>19</issue>):<fpage>1783</fpage>-<lpage>1784</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMp2101298</pub-id><pub-id pub-id-type="pmid">33983689</pub-id></mixed-citation></ref><ref id="aoi230049r46"><label>46</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Fiscella</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wakeman</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Beletsky</surname><given-names>L</given-names></string-name></person-group>. <article-title>Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver</article-title>. <source>JAMA Psychiatry</source>. <year>2019</year>;<volume>76</volume>(<issue>3</issue>):<fpage>229</fpage>-<lpage>230</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2018.3685</pub-id><pub-id pub-id-type="pmid">30586140</pub-id></mixed-citation></ref><ref id="aoi230049r47"><label>47</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Englander</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gregg</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Levander</surname><given-names>XA</given-names></string-name></person-group>. <article-title>Envisioning minimally disruptive opioid use disorder care</article-title>. <source>J Gen Intern Med</source>. <year>2023</year>;<volume>38</volume>(<issue>3</issue>):<fpage>799</fpage>-<lpage>803</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-022-07939-x</pub-id><pub-id pub-id-type="pmid">36401107</pub-id><pub-id pub-id-type="pmcid">PMC9676870</pub-id></mixed-citation></ref><ref id="aoi230049r48"><label>48</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Hayes</surname><given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Jakubowski</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fitzsimmons</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Garcia</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ramirez</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Fox</surname><given-names>AD</given-names></string-name></person-group>. <article-title>&#8220;The doctor says you cannot have [buprenorphine]&#8221; autonomy and use of prescribed or non-prescribed buprenorphine</article-title>. <source>Subst Use Misuse</source>. <year>2021</year>;<volume>56</volume>(<issue>8</issue>):<fpage>1137</fpage>-<lpage>1143</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10826084.2021.1908360</pub-id><pub-id pub-id-type="pmid">33939937</pub-id><pub-id pub-id-type="pmcid">PMC8754088</pub-id></mixed-citation></ref><ref id="aoi230049r49"><label>49</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lister</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Weaver</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ellis</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Himle</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Ledgerwood</surname><given-names>DM</given-names></string-name></person-group>. <article-title>A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States</article-title>. <source>Am J Drug Alcohol Abuse</source>. <year>2020</year>;<volume>46</volume>(<issue>3</issue>):<fpage>273</fpage>-<lpage>288</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00952990.2019.1694536</pub-id><pub-id pub-id-type="pmid">31809217</pub-id></mixed-citation></ref><ref id="aoi230049r50"><label>50</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Alegr&#237;a</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Frank</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Hansen</surname><given-names>HB</given-names></string-name>, <string-name name-style="western"><surname>Sharfstein</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Shim</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Tierney</surname><given-names>M</given-names></string-name></person-group>. <article-title>Transforming mental health and addiction services</article-title>. <source>Health Aff (Millwood)</source>. <year>2021</year>;<volume>40</volume>(<issue>2</issue>):<fpage>226</fpage>-<lpage>234</lpage>. doi:<pub-id pub-id-type="doi">10.1377/hlthaff.2020.01472</pub-id><pub-id pub-id-type="pmid">33476189</pub-id></mixed-citation></ref><ref id="aoi230049r51"><label>51</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Martin</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Chiodo</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Bosse</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>A</given-names></string-name></person-group>. <article-title>The next stage of buprenorphine care for opioid use disorder</article-title>. <source>Ann Intern Med</source>. <year>2018</year>;<volume>169</volume>(<issue>9</issue>):<fpage>628</fpage>-<lpage>635</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M18-1652</pub-id><pub-id pub-id-type="pmid">30357262</pub-id></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-AOI230049-1"><supplementary-material id="note-AOI230049-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p>
eMethods
</p><p><bold>eTable 1:</bold> U.S. state of all patients (n=3,395)</p><p><bold>eTable 2:</bold> Clinician rates of completed UDS per patient year, by month in care</p><p><bold>eTable 3:</bold> Urine drug screen results during baseline (first urine drug screen within 30 days of initiating treatment) and follow-up (closest urine drug screen to 180 days after initiating treatment, between 150 and 210 days after initiating treatment) (n=1,178)</p><p><bold>eTable 4:</bold> Urine drug screen results during baseline (first urine drug screen within 30 days of initiating treatment) and follow-up (closest urine drug screen to 180 days after initiating treatment, between 90 and 270 days after initiating treatment) (n=1,904)</p><p><bold>eTable 5:</bold> Urine drug screen results during baseline (within 30 days of initiating treatment) by whether or not patient has a urine drug screen during follow-up (between 120 and 240 days after initiating treatment) (n=2,782)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamahealthforum-e232247-s001.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p>
Data Sharing Statement
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamahealthforum-e232247-s002.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></notes></back></article></pmc-articleset>